Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell
death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is
associated with a diminished functionality in HIV-1 specific-CD8+ T cells. It is thought that
PD-1 blockade could contribute to reinvigorate antiviral immunity and reduce the HIV-1
reservoir. Methods: Upon metastatic melanoma diagnosis, an HIV-1-infected individual on
stable suppressive antiretroviral regimen was treated with pembrolizumab. A PET-CT was …
death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is
associated with a diminished functionality in HIV-1 specific-CD8+ T cells. It is thought that
PD-1 blockade could contribute to reinvigorate antiviral immunity and reduce the HIV-1
reservoir. Methods: Upon metastatic melanoma diagnosis, an HIV-1-infected individual on
stable suppressive antiretroviral regimen was treated with pembrolizumab. A PET-CT was …
以上显示的是最相近的搜索结果。 查看全部搜索结果